Comparability Issues Interfere with Another Erbitux Fiing
ImClone Systems, a subsidiary of Eli Lilly and Company (Indianapolis, Indiana), and Bristol-Myers Squibb (BMS, New York, NY), have received a complete response letter from the US Food and Drug Administration for the first-line squamous cell carcinoma of the head and neck supplemental Biologics License Application (sBLA) for Erbitux (cetuximab).
ImClone Systems, a subsidiary of Eli Lilly and Company (Indianapolis, Indiana), and Bristol-Myers Squibb (BMS, New York, NY), have received a complete response letter from the US Food and Drug Administration for the first-line squamous cell carcinoma of the head and neck supplemental Biologics License Application (sBLA) for Erbitux (cetuximab).
The FDA is requesting an additional pharmacokinetic study to confirm the comparability of the Erbitux used in the first-line head and neck submission as compared to Erbitux currently marketed in the US. Clinical supplies used in this sBLA were provided by Merck KGaA (Whitehouse Station, NJ), ImClone’s partner for Erbitux outside of North America.
As previously announced, ImClone and BMS recently withdrew the advanced non-small cell lung cancer sBLA for Erbitux because of the same problem. (See the February BioPharm bulletin.)In both cases, the companies are continuing to work with the FDA to confirm pharmacokinetic comparability.
The companies’ discussions with the FDA do not have any effect on currently marketed Erbitux, including the safety and efficacy of the product for approved indications.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
